- Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg twice daily; Drug: dolutegravir placebo twice daily; Drug: Open-label dolutegravir 50mg twice daily
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: darunavir/cobicistat/emtricitabine/GS-7340; Drug: darunavir + cobicistat + emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: HIV
Interventions: Genetic: SB-728-T; Genetic: SB-728-T; Genetic: SB-728-T
Sponsors: Sangamo Biosciences; Sangamo Biosciences
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Intervention: Drug: Sevelamer carbonate
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: NNRTI plus FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1 Infection
Interventions: Drug: BMS-986001; Drug: BMS-986001; Drug: BMS-986001; Drug: Placebo matching with BMS-986001; Drug: Efavirenz; Drug: Lamivudine; Drug: Tenofovir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir-boosted protease inhibitor plus Truvada
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1 Infection
Interventions: Drug: Pravastatin sodium; Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate; Drug: Pravastatin sodium
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: HIV Infection
Interventions: Dietary Supplement: Probiotics; Dietary Supplement: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Not yet recruiting - verified November 2011 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Ribavirin; Biological: peginterferon alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Biological: Quadrivalent HPV Vaccine; Biological: Placebo Vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: HIV Infection
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified November 2011 - Condition: HIV-1 Infection
Intervention: Drug: Rifaximin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: Cobicistat; Drug: Darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified October 2011 - Condition: HIV Infection
Intervention: Drug: Polyphenon E
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified September 2011 - Conditions: HIV; AIDS; Peripheral Neuropathy; Pain; Sleep
Interventions: Device: Splinting application to the lower extremities; Device: Splint liner application
Sponsors: Texas Woman's University; Texas Woman's University; Harris County Hospital District; DJO Incorporated
Recruiting - verified March 2012 - Conditions: Leukemia; Lymphoma; HIV
Interventions: Drug: Fludarabine and Busulfan (Flu/Bu); Drug: Fludarabine and Melphalan (Flu/Mel); Drug: Busulfan and Fludarabine (Bu/Flu); Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI); Drug: Fludarabine; Drug: Busulfan, Fludarabine, Cyclophosphamide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Device: Ventripoint Medical System
Sponsors: VentriPoint Diagnostics Ltd.; VentriPoint Diagnostics Ltd.
Recruiting - verified April 2012 - Conditions: Liver Diseases, Alcoholic; Alcoholism; HIV; Hepatitis C
Interventions: Other: Integrated Stepped Care (ISC); Other: Treatment as Usual
Sponsors: Yale University; Yale University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Department of Veterans Affairs
Not yet recruiting - verified August 2011 - Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: HIV-1 Infection
Interventions: Drug: Atripla; Drug: Calcium Carbonate; Drug: Vitamin D3; Drug: Placebo for calcium carbonate; Drug: Placebo for vitamin D3
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI201335; Drug: BI201335 24W; Drug: PegIFN/RBV; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Human Immunodeficiency Virus-1
Interventions: Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: Raltegravir; Drug: Raltegravir; Drug: Tenofovir; Drug: Tenofovir; Drug: Ritonavir; Drug: Atazanavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: HIV Prevention
Intervention: Drug: Tenofovir 1% vaginal gel
Sponsors: CONRAD; CONRAD
Recruiting - verified March 2012 - Condition: Human Immunodeficiency Virus (HIV) Infection
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF; Drug: cobicistat and atazanavir or cobicistat and darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: HIV-1 Infection
Interventions: Drug: Cenicriviroc 100 mg; Drug: Cenicriviroc 200 mg + Truvada; Drug: Sustiva + Truvada
Sponsors: Tobira Therapeutics, Inc.; Tobira Therapeutics, Inc.
Recruiting - verified October 2011 - Condition: HIV Disease
Interventions: Drug: HAART regimen; Drug: 3TC or FTC monotherapy
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: HIV Lipodystrophy
Interventions: Drug: mecasermin; Drug: Placebo control
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012 - Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: dolutegravir
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: HIV Coinfection; Hepatitis C; Hepatitis B; Hepatotoxicity
Interventions: Drug: Maraviroc; Drug: Placebo
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: Acquired Immunodeficiency Syndrome
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified October 2011 - Condition: HIV Infection
Intervention: Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Abbott
Recruiting - verified May 2012 - Conditions: HIV; Sexually Transmitted Diseases
Intervention: Behavioral: It's Your Game Tech
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; National Institute of Mental Health (NIMH)
Recruiting - verified March 2012 - Condition: HIV Infections
Interventions: Biological: Profectus HIV MAG pDNA vaccine; Biological: IL-12; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Interventions: Drug: atorvastatin; Drug: atorvastatin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Pfizer
Recruiting - verified September 2011 - Condition: ADHD
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting - verified May 2012 - Condition: HIV
Intervention: Drug: Tenofovir/emtricitabine and raltegravir
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Merck; Gilead Sciences
Recruiting - verified February 2012 - Conditions: Anal Cancer; Nonneoplastic Condition; Penile Cancer; Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Lymphoma; HIV
Intervention: Procedure: Autologous transplant
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified January 2012 - Conditions: HIV-1 Infection; Neuropathic Pain
Intervention: Drug: pregabalin (Lyrica)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention: Procedure: Blood collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions: Drug: rituximab; Drug: etoposide; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: HIV Infections
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Nonneoplastic Condition; Sarcoma
Interventions: Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Drug: Alendronate; Drug: Alendronate placebo; Dietary Supplement: Calcium carbonate/vitamin D
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; Kirby Institute; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified April 2012 - Condition: HIV Infections
Interventions: Biological: DNA plasmid vaccine; Biological: Recombinant adenoviral serotype 5 (rAD5) vector vaccine; Biological: DNA vaccine placebo; Biological: HIV-1 recombinant adenovirus vaccine placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine Trials Network
Recruiting - verified May 2012 - Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1; Drug: UK-453,061 Dose 2; Drug: Etravirine
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: HIV-1
Interventions: Drug: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: HIV Infections; HIV-1
Intervention: Drug: TMC278
Sponsors: Tibotec Pharmaceuticals, Ireland; Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2012 - Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: Human Immunodeficiency Virus Infections
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Aids-related Malignancies; Lymphoma; Precancerous Condition; Sarcoma
Interventions: Genetic: polymerase chain reaction; Other: cytology specimen collection procedure; Other: histological technique; Procedure: colposcopic biopsy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Conditions: HIV Infections; Hyperlipidemia
Intervention: Drug: Atorvastatin
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Conditions: HIV Infections; Lipodystrophy
Intervention: Drug: Metreleptin (Leptin)
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Amylin Pharmaceuticals, Inc.
Recruiting - verified August 2011 - Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Available - verified January 2012 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2012 - Condition: HIV Infections
Intervention: Drug: Current ARV medications
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2012 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Conditions: HIV Infections; Pregnancy Complications, Infectious
Intervention: Behavioral: Adherence assessment
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Conditions: AIDS Associated Nephropathy; Focal Glomerulosclerosis; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011


